Project Grant R01HL176686
Award Date
5/1/25
Completion Date
2/28/29
Dollars Obligated
$812K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
This Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), aims to develop and validate a quantitative marker of pulmonary microvascular injury to explore the relationship between microvascular volume loss and the progression of chronic obstructive pulmonary disease (COPD) and emphysema in smokers. The $268,500 award to Brigham & Women's Hospital Inc., a subsidiary of Partners Healthcare System...
This Project Grant award, valued at $131,783 and awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports a research study focused on identifying blood and lung fluid biomarkers for phenotypes and acute exacerbations of chronic obstructive pulmonary disease (COPD). The study protocol will enroll COPD patients undergoing bronchoscopic lung volume reduction procedures, as well as stable subjects with and without...
This $245,626 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), aims to validate lipidomic signatures associated with right ventricular-pulmonary vascular (RV-PV) dysfunction and clinical outcomes in external patient cohorts. The primary goals are to: 1) Validate the lipidomic signatures identified in the researchers' discovery cohort within the larger, multi-center PVDOMICS cohort, and examine...
The federal Project Grant award R01HL174648 for $626,247.00, awarded by the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) on September 1, 2024, supports research to develop a tool to identify undiagnosed individuals with chronic obstructive pulmonary disease (COPD) using quantitative imaging data from lung cancer screening. The research aims to characterize COPD-related lung pathology from low-dose computed tomography (LDCT) scans and create a risk...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $692,768 in funding to Rhode Island Hospital, a division of Lifespan Corporation, from March 1, 2025 through December 31, 2028. The grant supports research to define endothelial cell dysfunction in pulmonary arterial hypertension (PAH) and identify factors that influence endophenotypes. The central hypothesis is that anoikis...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $708,063 to the University of Virginia to conduct research on post-transcriptional regulatory networks in chronic obstructive pulmonary disease (COPD). The key objectives are to: Develop a method to identify RNA-binding protein (RBP) to isoform regulatory networks by integrating RBP binding assays and lung COPD transcriptomics...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $794,681 to Brigham & Women's Hospital, Inc. to develop a population-based analytics and data infrastructure to evaluate the impact of non-COPD medications on outcomes for patients with chronic obstructive pulmonary disease (COPD). The project aims to leverage electronic health data and advanced computational tools to identify potential drug...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research Federal Grant Program (CFDA 93.837), provides $167,940 to The Children's Hospital Corporation (doing business as Boston Children's Hospital) to develop a new mouse model of flow-induced pulmonary hypertension (PH) that better represents the physiological conditions of patients with congenital heart disease (CHD). The project aims to gain key insights into the...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $604,115.00 to The General Hospital Corporation (doing business as Massachusetts General Hospital) for a longitudinal observational study. The study aims to determine if advanced PET and MRI imaging technologies can predict which individuals with non-IPF interstitial lung disease (ILD) will develop progressive pulmonary fibrosis...
This federal Project Grant award of $5,715,866.00 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) aims to develop novel, transformative therapies to substantially reduce the burden of morbidity and mortality from progressive pulmonary fibrosis (PF). The award, with a performance period from September 2024 to July 2029, will fund four projects and three cores to re-shape the understanding of PF natural history by investigating the...